Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program

•Measures have to be taken to avoid contamination of Ebola virus disease contacts•Monoclonal antibodies (mAbs) appear to be interesting candidates for prophylaxis•No contamination was found among contacts treated with mAbs With the development of therapeutics and vaccine against Ebola virus disease...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of infectious diseases Vol. 113; pp. 166 - 167
Main Authors:	Jaspard, Marie, Juchet, Sylvain, Serra, Béatrice, Mayoum, Baweye, Kanta, Issa Malam, Camara, Mohamed Seto, Mbala, Placide, Kojan, Richard, Malvy, Denis
Format:	Journal Article
Language:	English
Published:	Canada Elsevier Ltd 01-12-2021 Elsevier
Subjects:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Democratic Republic of the Congo - epidemiology Disease Outbreaks Drug Combinations Ebola virus disease Ebolavirus Emerging diseases Hemorrhagic Fever, Ebola - drug therapy Hemorrhagic Fever, Ebola - prevention & control Human health and pathology Humans Immunology Immunotherapy Infectious diseases Life Sciences monoclonal antibodies Post-Exposure Prophylaxis Santé publique et épidémiologie Democratic Republic of the Congo post-exposure prophylaxis Ebola virus disease monoclonal antibodies Monoclonal antibodies Post-exposure prophylaxis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Measures have to be taken to avoid contamination of Ebola virus disease contacts•Monoclonal antibodies (mAbs) appear to be interesting candidates for prophylaxis•No contamination was found among contacts treated with mAbs With the development of therapeutics and vaccine against Ebola virus disease (EVD), the question of post-exposure prophylaxis for high-risk contact has emerged. Immunotherapies (monoclonal antibodies [mAbs]) recently validated for treating infected patients appear to be a good candidate for protecting contacts. During the tenth EVD outbreak in the Democratic Republic of the Congo, we have administrated mAbs (Mab114 or REGN-EB3) to high and intermediate-risk contacts of EVD patients. : Overall, 23 non-vaccinated contacts received mAbs after a median delay between contact and post-exposure prophylaxis of 1 day (interquartile range 1–2). All contacts were free of symptoms, and all had negative reverse transcriptase-polymerase chain reaction 14 days after the contact. Immunotherapies appear to be promising candidates to protect EVD contacts. Interaction with vaccine needs to be analyzed and a larger study on efficacy conducted.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1201-9712 1878-3511
DOI:	10.1016/j.ijid.2021.09.053